TheraRadar

Pharma Intelligence, Simplified

Landscape → CNS

Alcohol Use Disorder

277 clinical trials

109 active
/
277 total (since 2015)
24
Phase 1 Active
72 total
81
Phase 2 Active
185 total
16
Phase 3 Active
42 total
4
Phase 4 Active
18 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Eli Lilly 3 0 0
Afasci Inc 2 0 0
Pop Test Oncology LLC 1 2 0
Imbrium Therapeutics 1 1 0
Shenzhen Sciencare Medical Industries Co., Ltd. 1 0 0
Altimmune, Inc. 1 0 0
Inventage Lab., Inc. 1 0 0
Tempero Bio, Inc. 1 0 0
Clearmind Medicine Inc. 1 0 0
Evon Medics LLC 1 0 0
Otsuka Pharmaceutical Co., Ltd. 0 3 0
NCT07219953 RECRUITING
A Study of Brenipatide in Participants With Alcohol Use Disorder
Eli Lilly and Company n=1,100
NCT07219966 RECRUITING
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Eli Lilly and Company n=1,100
NCT07433413 NOT YET RECRUITING
Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder
Shenzhen Sciencare Medical Industries Co., Ltd. n=240
NCT07118839 NOT YET RECRUITING
MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder
VA Office of Research and Development n=80
NCT04616781 RECRUITING
Ketone Ester Intervention in Alcohol Use Disorder
University of Pennsylvania n=20
NCT07148843 NOT YET RECRUITING
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Johns Hopkins University n=105
NCT07218354 NOT YET RECRUITING
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder
VA Office of Research and Development n=438
NCT06790342 NOT YET RECRUITING
Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya
University of Chicago n=300
NCT06807918 NOT YET RECRUITING
Effects of Ketones on Brain Energetics and Alcohol Consumption in Alcohol Use Disorder
University of Pennsylvania n=60
NCT06559995 RECRUITING
Effects of Ketone Supplementation on Alcohol Withdrawal and Brain Metabolism in Alcohol Use Disorder
University of Pennsylvania n=30
NCT06702007 RECRUITING
Electronic Harm Reduction Treatment for Alcohol
University of Washington n=160
NCT05827159 RECRUITING
Emergency Department-Initiated Medications for Alcohol Use Disorder
Yale University n=240
NCT05015881 ENROLLING BY INVITATION
Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder
University of Pennsylvania n=20
NCT06173973 ENROLLING BY INVITATION
Effects of Ketone Supplementation on Acute Alcohol Withdrawal
University of Pennsylvania n=50
NCT04971577 RECRUITING
Efficacy of Simvastatin in Alcoholic Liver Fibrosis
Anna Cruceta n=90
NCT05613608 RECRUITING
Alcohol Use Disorder and Cannabidiol
University of Colorado, Denver n=180
NCT06143059 SUSPENDED
The Effects of Sex Hormones and Alcohol on Sleep
Lauren Whitehurst n=130
NCT05748639 COMPLETED
Integrated Digital Intervention for Alcohol Use Disorder
Quit Genius n=242
NCT04098302 COMPLETED
Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy
UConn Health n=180
NCT02918370 COMPLETED
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
University of Texas Southwestern Medical Center n=75
NCT03634917 COMPLETED
Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence
Technische Universität Dresden n=82
NCT04101227 COMPLETED
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms
Adial Pharmaceuticals n=302
NCT05093296 COMPLETED
Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder
Central Institute of Mental Health, Mannheim n=62
NCT02884908 COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD
University of Maryland, Baltimore n=57
NCT05458609 COMPLETED
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep
Baylor College of Medicine n=8
NCT04603781 SUSPENDED
CBD Oil for Reducing Emotional Impact of COVID-19
University of Texas at Austin n=200
NCT03176953 COMPLETED
Topiramate and Prolonged Exposure
VA Office of Research and Development n=100
NCT02824354 WITHDRAWN
Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.
Centre Hospitalier Universitaire, Amiens
NCT02901041 COMPLETED
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
Boston University Charles River Campus n=81
NCT02187224 COMPLETED
Progesterone Effect on Individuals Diagnoses With AD and PTSD.
Yale University n=13
NCT03539887 COMPLETED
Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse
The University of Texas Health Science Center, Houston n=33
NCT02900352 COMPLETED
Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action
Virginia Commonwealth University n=156
NCT02368431 TERMINATED
Effectiveness of Zonisamide in Alcohol Dependent Veterans
VA Office of Research and Development n=92
NCT02382276 COMPLETED
A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence
Otsuka Pharmaceutical Co., Ltd. n=405
NCT04318639 COMPLETED
The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder
VA Connecticut Healthcare System n=15
NCT03339024 COMPLETED
Intranasal Oxytocin Effects in Alcohol Withdrawal and Dependence; Follow-up Study
Norwegian University of Science and Technology n=38
NCT02358226 COMPLETED
HIV & Drug Abuse Prevention for South African Men
University of California, Los Angeles n=1,211
NCT02539511 COMPLETED
Glutamatergic Modulation of Disordered Alcohol Use
New York State Psychiatric Institute n=50
NCT02723383 COMPLETED
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU
Nantes University Hospital n=314
NCT02364947 COMPLETED
A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)
Otsuka Pharmaceutical Co., Ltd. n=678
NCT02903251 COMPLETED
Oxytocin and Alcohol Withdrawal and Dependence
Norwegian University of Science and Technology n=40
NCT02652585 COMPLETED
Validation of a Test System for Development of Medications for Alcoholism
Technische Universität Dresden n=46

Data: ClinicalTrials.gov